Regulatory watch: Surprise setback for lung fibrosis drug highlights trial challenges.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D017277:Drug Approval; D006801:Humans; D011658:Pulmonary Fibrosis / Q000188:drug therapy* / Q000473:pathology; D011728:Pyridones / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011728:Pyridones; C093844:pirfenidone